Literature DB >> 25741170

Complete remission of advanced hepatocellular carcinoma by radiofrequency ablation after sorafenib therapy.

Jung Gil Park1, Soo Young Park1, Hye Won Lee1.   

Abstract

Sorafenib, a potent multikinase inhibitor, lead to a significant improvement in progression free survival and overall survival in patients with advanced hepatocellular carcinoma (HCC). Though sorafenib has proven its efficacy in advanced stage HCC, there are limited reports on the role of sorafenib allowing for curative treatment by down-staging. We herein report a case of advanced HCC with vascular invasion, which showed treatment response by sorafenib therapy as to allow for radiofrequency ablation as curative treatment. The patient was followed-up for 6 mo without recurrence with continued sorafenib therapy.

Entities:  

Keywords:  Complete remission; Down-staging; Hepatocellular carcinoma; Radiofrequency ablation; Sorafenib

Mesh：

Substances：

Year:  2015        PMID： 25741170      PMCID： PMC4342939          DOI： 10.3748/wjg.v21.i8.2568

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN： 1007-9327            Impact factor:   5.742


  18 in total

Review 1.  Overview: Where does radiation therapy fit in the spectrum of liver cancer local-regional therapies?

Authors:  Laura A Dawson
Journal:  Semin Radiat Oncol       Date:  2011-10       Impact factor: 5.934

2.  Sustained remission over 36 months of advanced hepatocellular carcinoma after short-term sorafenib therapy.

Authors:  Sun Young Ahn; Hyun Seok Lee; Young Oh Kweon; Won Young Tak; Soo Young Park
Journal:  Dig Dis Sci       Date:  2013-01-10       Impact factor: 3.199

3.  Global cancer statistics, 2002.

Authors:  D Max Parkin; Freddie Bray; J Ferlay; Paola Pisani
Journal:  CA Cancer J Clin       Date:  2005 Mar-Apr       Impact factor: 508.702

4.  Complete regression of locally advanced hepatocellular carcinoma induced by sorafenib allowing curative resection.

Authors:  Sabine Irtan; Xavier Chopin-Laly; Maxime Ronot; Sandrine Faivre; Valérie Paradis; Jacques Belghiti
Journal:  Liver Int       Date:  2011-01-11       Impact factor: 5.828

5.  Doxorubicin plus sorafenib vs doxorubicin alone in patients with advanced hepatocellular carcinoma: a randomized trial.

Authors:  Ghassan K Abou-Alfa; Philip Johnson; Jennifer J Knox; Marinela Capanu; Irina Davidenko; Juan Lacava; Thomas Leung; Bolorsukh Gansukh; Leonard B Saltz
Journal:  JAMA       Date:  2010-11-17       Impact factor: 56.272

6.  Complete remission of unresectable hepatocellular carcinoma treated with reduced dose of sorafenib: a case report.

Authors:  Sean Xiang Wang; Abigail Byrnes; Sadhna Verma; John R Pancoast; Olivier Rixe
Journal:  Target Oncol       Date:  2010-03-23       Impact factor: 4.493

Review 7.  Multidisciplinary management of hepatocellular carcinoma: where are we today?

Authors:  Jorge A Marrero
Journal:  Semin Liver Dis       Date:  2013-03-01       Impact factor: 6.115

8.  Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial.

Authors:  Ann-Lii Cheng; Yoon-Koo Kang; Zhendong Chen; Chao-Jung Tsao; Shukui Qin; Jun Suk Kim; Rongcheng Luo; Jifeng Feng; Shenglong Ye; Tsai-Sheng Yang; Jianming Xu; Yan Sun; Houjie Liang; Jiwei Liu; Jiejun Wang; Won Young Tak; Hongming Pan; Karin Burock; Jessie Zou; Dimitris Voliotis; Zhongzhen Guan
Journal:  Lancet Oncol       Date:  2008-12-16       Impact factor: 41.316

9.  The efficacy of intraperitoneal saline infusion for percutaneous radiofrequency ablation for hepatocellular carcinoma.

Authors:  Soo Young Park; Won Young Tak; Seong Woo Jeon; Chang Min Cho; Young Oh Kweon; Sung Kook Kim; Yong Hwan Choi
Journal:  Eur J Radiol       Date:  2009-04-23       Impact factor: 3.528

10.  Sorafenib in advanced hepatocellular carcinoma.

Authors:  Josep M Llovet; Sergio Ricci; Vincenzo Mazzaferro; Philip Hilgard; Edward Gane; Jean-Frédéric Blanc; Andre Cosme de Oliveira; Armando Santoro; Jean-Luc Raoul; Alejandro Forner; Myron Schwartz; Camillo Porta; Stefan Zeuzem; Luigi Bolondi; Tim F Greten; Peter R Galle; Jean-François Seitz; Ivan Borbath; Dieter Häussinger; Tom Giannaris; Minghua Shan; Marius Moscovici; Dimitris Voliotis; Jordi Bruix
Journal:  N Engl J Med       Date:  2008-07-24       Impact factor: 91.245
View more
  3 in total

1.  (125)I-labeled anti-bFGF monoclonal antibody inhibits growth of hepatocellular carcinoma.

Authors:  Peng-Hui Hu; Lan-Hong Pan; Patrick Ting-Yat Wong; Wen-Hui Chen; Yan-Qing Yang; Hong Wang; Jun-Jian Xiang; Meng Xu
Journal:  World J Gastroenterol       Date:  2016-06-07       Impact factor: 5.742

2.  Notch1 regulates the JNK signaling pathway and increases apoptosis in hepatocellular carcinoma.

Authors:  Chengxu Sui; Chengjun Zhuang; Deguang Sun; Li Yang; Liang Zhang; Lei Song
Journal:  Oncotarget       Date:  2017-07-11

3.  Pathological complete response by advanced hepatocellular carcinoma with massive macrovascular invasion to hepatic arterial infusion chemotherapy: a case report.

Authors:  Shusei Sano; Shinji Nakata; Shuichi Wada; Masatsugu Kuroiwa; Hiroki Sakai; Kei Kusama; Taiichi Machida; Akihito Nishio; Ichiro Ito; Harutsugu Sodeyama
Journal:  World J Surg Oncol       Date:  2019-12-26       Impact factor: 2.754
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.